



First Patient Dosed in CEP-2 Sarcoma Trial at the prestigious US City of Hope Cancer Center

Highlights

- First patient treated in Noxopharm's CEP-2 trial at the prestigious US City of Hope Cancer Center
- Recruitment is ongoing and first safety results will follow
- List of top-ranked cancer hospitals currently investigating Veyonda® is growing

Sydney 28 February 2022: Australian clinical-stage drug development company **Noxopharm Limited (ASX:NOX)** is pleased to announce the first patient in its phase 1 CEP-2 trial has been enrolled and dosed at the prestigious City of Hope Cancer Center, California.

Patient recruitment is ongoing, and the Company expects to open further US trial sites in due course. The first safety results will be reported once patient cohort 1 has completed the first cycle of combination therapy.

The City of Hope Cancer Center is an influential medical institution and is considered one of the most world-renowned cancer hospitals in the USA according to the US News & World Report. It is consistently ranked as a top cancer treatment centre in the US and is also a founding member of the National Comprehensive Cancer Network, a non-profit alliance of 21 US cancer centres that publishes clinical practice guidelines for cancer treatment.

Dr Mark Agulnik, CEP-2 Principal Investigator at the City of Hope Cancer Center, said: "We are delighted to have dosed the first patient in the CEP-2 trial. The study investigates the use of Veyonda in combination with the chemotherapy drug doxorubicin for the treatment of approximately 30 patients with soft tissue sarcoma, which is an aggressive cancer in urgent need of new treatment options."

The CEP-2 study builds on the findings from CEP-1, as published in the peer-reviewed journal *Current Therapeutic Research* (announced 30 April 2021).

Noxopharm CEO Dr Gisela Mautner stated: "Noxopharm is a young and agile Australian biotech company which has managed to attract the depth of talent and experience needed to work with prestigious US institutions such as City of Hope for the CEP-2 study, along with MD Anderson Cancer Center and Beverly Hills Cancer Center for our DARRT program. We look forward to adding additional world-renowned study sites in the near future."

- ENDS -

About the CEP-2 Trial

CEP-2 is a Phase 1, open-label, dose-escalation and dose-expansion study of Veyonda® administered to cohorts of patients being treated with doxorubicin for the treatment of metastatic soft tissue sarcoma. Approximately 30 patients in the United States with a range



of soft tissue sarcomas are being enrolled to be treated with the Veyonda / doxorubicin combination as a first-line treatment.

A number of major sites are participating in CEP-2, the first, the City of Hope Cancer Center in Los Angeles has commenced treatment, with other sites to be activated shortly.

The CEP-Program is based on pre-clinical and clinical findings of Veyonda enhancing the anti-cancer effect of a number of standard chemotherapeutic agents.

The findings from the CEP-1 clinical trial have been published in *Current Therapeutic Research* in April 2021.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and inflammation. Veyonda® is the Company's first pipe-line drug candidate currently in Phase 1 and 2 clinical trials.

Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of the US biotechnology company, Nyrada Inc (ASX:NYR), active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.